Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01580241 | Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer | active not recruiting | — | 60 | University of OklahomaOTHER | 1 | Apr 1, 2026 |
| NCT05871164 | Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency(RAFPAN2) | recruiting | — | 200 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06953193 | Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia | recruiting | N/A | 206 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05380414 | Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients | recruiting | N/A | 750 | Centre Leon BerardOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | recruiting | Phase 3 | 274 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 66 | Recurv Pharma IncINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07504471 | Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases | recruiting | Phase 2 | 50 | Ruijin HospitalOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03060720 | Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy | active not recruiting | — | 271 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy(ACTION-1) | recruiting | Phase 3 | 338 | RayzeBio, Inc.INDUSTRY | 8 | Mar 30, 2026 | clinicaltrials |
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07144917 | Immunoparalysis After Pancreaticoduodenectomy(ImPaHLA) | recruiting | — | 100 | Hospices Civils de LyonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04281290 | Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)(PanECT) | active not recruiting | N/A | 10 | University Medical Centre LjubljanaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05788744 | Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer(CIRCPAC) | recruiting | N/A | 1,000 | Copenhagen University Hospital at HerlevOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07324096 | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer(AI-PACED) | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07486128 | Microplastics in Pancreas: Oncologic and Metabolic Impact(PAN-Plastic) | not yet recruiting | — | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05847855 | Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493421 | To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. | recruiting | N/A | 20 | Unidade Local de Saúde São JoãoOTHER_GOV | 2 | Mar 25, 2026 | clinicaltrials |
| NCT05961982 | Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study(ERASE) | recruiting | N/A | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03218345 | EUS-guided RFA for Pancreatic Neoplasms | recruiting | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04894643 | Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer(PARC) | recruiting | N/A | 10 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05128890 | Evaluation of Resection Techniques for Pancreatic Tumors | recruiting | — | 431 | Methodist Health SystemOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05191940 | Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)(LAPC) | recruiting | N/A | 30 | EBG MedAustron GmbHINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07470268 | Impact of Hypertrophy-oriented Resistance Training on Muscle Mass and Quality of Life in Patients With Unresectable Pancreatic Cancer(HY-PANC) | not yet recruiting | N/A | 10 | Universidad Europea de MadridOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07477418 | PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)(PRISM-TAMP) | not yet recruiting | Phase 1 / Phase 2 | 10 | University of VermontOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05601323 | A Study of Suizenji in Patients With Unresectable Pancreatic Cancer | active not recruiting | N/A | 90 | SONIRE Therapeutics Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06756074 | Reinforced Pancreaticojejunostomy With or Without glubran2 | recruiting | Phase 2 | 100 | Minia UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | recruiting | Phase 2 | 88 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06712797 | Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center(PANTHER-PIC) | active not recruiting | N/A | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07469956 | Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04472910 | GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma(NeoPancOne) | active not recruiting | N/A | 84 | University Health Network, TorontoOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06151223 | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer | recruiting | — | 5,000 | Mayo ClinicOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06821503 | Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C | recruiting | Phase 1 / Phase 2 | 72 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | recruiting | — | 20,000 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07254091 | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 10 | Northwell HealthOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00899626 | Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients | recruiting | — | 5,000 | Vanderbilt University Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 2, 2026source: clinicaltrials